High Growth Tech Companies To Watch In November 2024

As global markets navigate a complex landscape marked by busy earnings reports and economic data, the technology sector remains a focal point, with indices such as the Nasdaq Composite experiencing volatility after reaching record highs. In this dynamic environment, identifying high-growth tech stocks requires careful consideration of their ability to innovate and adapt amidst cautious market sentiment and fluctuating economic indicators.

Top 10 High Growth Tech Companies

Name	Revenue Growth	Earnings Growth	Growth Rating
Material Group	20.45%	24.01%	★★★★★★
Yggdrazil Group	24.66%	85.53%	★★★★★★
eWeLLLtd	26.52%	27.53%	★★★★★★
Medley	24.98%	30.36%	★★★★★★
Seojin SystemLtd	33.39%	49.13%	★★★★★★
Sarepta Therapeutics	23.43%	41.52%	★★★★★★
Mental Health TechnologiesLtd	27.88%	79.61%	★★★★★★
Alnylam Pharmaceuticals	22.41%	70.53%	★★★★★★
Adveritas	57.98%	144.21%	★★★★★★
UTI	114.97%	134.60%	★★★★★★

Click here to see the full list of 1287 stocks from our High Growth Tech and AI Stocks screener.

Let's uncover some gems from our specialized screener.

BioArctic (OM:BIOA B)

Simply Wall St Growth Rating: ★★★★★★

Overview: BioArctic AB (publ) is a Swedish company focused on developing biological drugs for central nervous system disorders, with a market cap of approximately SEK13.37 billion.

Operations: BioArctic AB (publ) generates revenue primarily from its biotechnology segment, which amounted to SEK299.35 million. The company is engaged in the development of biological drugs targeting central nervous system disorders.

BioArctic, amidst a challenging backdrop for biotech firms, stands out with its robust pipeline and strategic R&D investments. The company's revenue is projected to surge by 42.4% annually, significantly outpacing the broader Swedish market's stagnation. This growth is underpinned by promising clinical advancements, notably in Alzheimer’s treatments like Leqembi®, which received multiple global approvals including the UAE, highlighting its international impact. Despite current unprofitability, BioArctic is expected to pivot into profitability within three years with an anticipated profit growth of 98.4% per year. Moreover, their recent presentation at the Clinical Trials on Alzheimer’s Disease conference underscores their active engagement in cutting-edge research and development efforts focused on neurological disorders—an area witnessing exponential demand and innovation.

• Click here to discover the nuances of BioArctic with our detailed analytical health report.

• Review our historical performance report to gain insights into BioArctic's's past performance.

Yubico (OM:YUBICO)

Simply Wall St Growth Rating: ★★★★★★

Overview: Yubico AB offers authentication solutions for computers, networks, and online services with a market capitalization of SEK23.12 billion.

Operations: The company generates revenue primarily from its Security Software & Services segment, amounting to SEK2.09 billion.

Yubico's strategic focus on enhancing cybersecurity is evident from its recent partnership with PKO Bank Polski, integrating YubiKeys for secure e-banking logins—a move critical in today’s high-risk digital environment. This aligns with their impressive 20.5% annual revenue growth forecast, outpacing the Swedish market significantly. Moreover, Yubico's commitment to innovation is underscored by a substantial 42.2% expected annual earnings growth and an aggressive R&D strategy that has seen R&D expenses climbing steadily, reflecting its dedication to maintaining a competitive edge in the cybersecurity sector. These factors collectively suggest Yubico's potential to adapt and thrive amidst evolving tech landscapes, despite facing challenges like a highly volatile share price and recent one-off losses impacting financial results.

• Click to explore a detailed breakdown of our findings in Yubico's health report.

• Examine Yubico's past performance report to understand how it has performed in the past.

Shenzhen Qingyi Photomask (SHSE:688138)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Shenzhen Qingyi Photomask Limited specializes in the research, design, production, and sales of high precision masks in China with a market cap of CN¥6.96 billion.

Operations: Qingyi Photomask focuses on high precision mask production and sales, leveraging its expertise in research and design to cater to the Chinese market.

Shenzhen Qingyi Photomask's recent performance showcases robust growth, with a 23.8% increase in sales to CNY 826.75 million over nine months, underpinning its strong market position in the photomask industry. This growth is complemented by a notable rise in net income to CNY 120.46 million, reflecting a strategic emphasis on operational efficiency and market expansion. Despite not engaging in share repurchases this quarter, the company has demonstrated prudent capital management by completing significant buybacks earlier this year, enhancing shareholder value. These financial metrics are pivotal as they align with the broader industry trends where technological advancements and capacity expansions are critical for maintaining competitiveness.

• Get an in-depth perspective on Shenzhen Qingyi Photomask's performance by reading our health report here.

• Learn about Shenzhen Qingyi Photomask's historical performance.

Seize The Opportunity

• Gain an insight into the universe of 1287 High Growth Tech and AI Stocks by clicking here.
• Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
• Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com